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INTRODUCTION
Tablets may be defined as solid pharmaceutical dosage 
forms containing drug substance with or without suitable 
diluents, prepared by either compression or molding1.
Advantages
 They are unit dosage forms and offer the greatest 
capabilities of all oral dosage forms for the greatest dose 
precision and the least content variability.
 Their cost is lowest of all oral dosage forms.
 They are the lightest and most compact of all oral dosage 
forms.
 Product identification is potentially simplest and cheapest, 
requiring no additional processing steps when employing 
an embossed (or) monogrammed punch face.
 They may provide the greatest ease of swallowing with the 
least tendency for “hang up” above the stomach, 
especially when coated, provided the tablet disintegration 
is not excessively rapid.
 They lend themselves to certain special release profile 
products, such as enteric (or) delayed release products.
 They are better suited to large-scale production than other 
unit oral dosage forms.
 They have the best-combined properties of chemical, 
mechanical and microbiological stability of all the oral 
dosage forms.
 Tablet is a tamper proof dosage form.
Disadvantages
 Drugs with poor wetting, slow dissolution properties, 
intermediate to large dosages or any combination of these 
features may be difficult (or) impossible to formulate and 
manufacture as a tablet.
 Some drugs resist compression into dense compact, owing 
to their amorphous nature (or) flocculent, low density 
character.
 Bitter tasting drugs, drugs with an objectionable odor (or) 
drugs that are sensitive to oxygen (or) atmospheric 
moisture may require encapsulation (or) the tablets may 
require coating. In such cases the capsule may offer the 
best and lowest cost approach.
Properties of Tablets
The attributes of an acceptable tablet are as follows:
1. The tablet must be sufficiently strong and resistant to 
shock and abrasion, to withstand handling during 
manufacture, packaging, shipping and use. This property 
is measured by two tests, the hardness and friability tests.
2. Tablets must be elegant in appearance and must have the 
characteristic shape, color, and other markings necessary 
to identify the product. Markings are usually the 
monogram (or) logo of the manufacturer.
3. Tablets often have the National Drug Code Compendium 
of the Food and Drug Administration. Another marking 
that may appear on the tablet is a score (or) crease across 
the face, which is intended to permit breaking the tablet 
into equal parts for the administration of half a tablet. 
However, it has been shown that substantial variation in 
drug dose can occur in the manually broken tablets.
4. Tablets must be uniform in weight and in drug content of 
the individual tablet. This is measured by the weight 
variation test and the content uniformity test.
5. The drug content of the tablet must be bioavailable. This 
property is also measured by two tests, the disintegration 
test and the dissolution test.
6. Bioavailability of a drug from a tablet (or) other 
dosage form is a very complex problem and the results of 
these two tests do not by themselves provide an index of 
bioavailability. This must be done by drug levels in blood.
7. Tablets must retain all of their functional attributes, which 
include drug stability and efficacy.
Ideal Characteristics of Tablet Dosage Form
 It has its own identity free of chips, cracks, discoloration 
and contamination.
 Should have strength to withstand vigorous mechanical 
shocks encounters in its production, packaging, shipping 
and dispensing.
 Should have chemical and physical stability.
On the other hand,
a. It must be able to release the medicinal agent in the body 
in a predictable and reproducible manner.
b. Must have a suitable chemical stability over time so as not 
to allow alterations of the medicinal agent.
c. Pre-compression of amorphous powders case negative 
effect on dissolution and disintegration rates.
Types and Classes of Tablets
Tablets are classified by their route of administration 
or function, by the type of drug delivery system they represent 
within that route, by their form and method of manufacture.
Tablets Ingested Orally
1) Compressed Tablets (CT)
2) Multiple Compressed Tablets (MCT)
a) Layered Tablets
b) Compression Coated Tablets
3) Repeat Action Tablets
4) Delayed Action and Enteric Coated Tablets
5) Sugar and Chocolate-Coated Tablets
6) Film Coated Tablets
7) Air Suspension Coated Tablets
8) Chewable Tablets
Tablets Used in Oral Cavity
1) Buccal Tablets
2) Sublingual Tablets
3) Troches, Lozenges and Dental Cone
Tablets Administered by Other Routes
1) Implantation Tablets
2) Vaginal Tablets
Tablets Used to Prepare Solution
1) Effervescent Tablets
2) Dispensing Tablets( DT)
3) Hypodermic Tablets(HT)
4) Tablet Triturate(TT)
Tabletting Methods
The four basic methods for the preparation of compressed 
tablets are8
1) Wet Granulation Method
2) Fluid- Bed Granulation
3) Dry Granulation Method and
4) Direct Compression
Wet Granulation
The most widely used and general method of tablet 
preparation is the wet granulation method. The steps involved 
in the wet method are weighing, mixing, wetting, granulation, 
screening the damp mass, drying, dry screening, lubrication 
and compression. The equipment involved depends on the 
quantity or size of the batch.
The active ingredients, diluents and disintegrants are 
mixed or blended well. For small batches the ingredients may 
be mixed in stainless steel bowls or mortars. The powder 
blend may be sifted through a screen of suitable fines to 
remove or break up lumps. This screening also affords 
additional mixing.
Solutions of the binding agents are added to the mixed 
powders with stirring. The powder mass is wetted with the 
binding solution until the mass has the consistency of damp 
snow or brown sugar. If the granulation is over wetted, the 
granules will be hard, requiring considerable pressure to form 
tablets and the resulted tablets will have mottled appearance. 
If the powder mixture is not wetted sufficiently, the resulting 
granules will be too soft, breaking down during lubrication 
and causing difficulty during compression.
The wet granulation is forced through a 6 or 8 mesh 
screen. For large quantities one of several comminuting mills 
like stokes tornado mill, stokes oscillator, etc. can be used.
Moist materials from the wet milling step is placed on 
large sheets of paper on shallow wire trays and placed in 
drying cabinets with a circulating air current and thermostatic 
heat control. Now-a-days fluid bed dryers are used. In drying 
granules it is desirable to maintain a residual amount of 
moisture in the granules. This is necessary to maintain the 
various granulation ingredients such as gums in a hydrated 
state. Residual moisture also contributes to the reduction of 
static electric charges on particles.
After drying, the granulation is reduced in particle size 
by passing it through smaller mesh screen. Following dry 
screening, the granules tend to be more uniform.
The lubricants are added as fine powders after dry 
granulation. It is usually screened through 60 or 100 mesh 
nylon cloth to eliminate lumps as well as to increase the 
covering power of the lubricants. The lubricants are blended 
with the granules very gently, preferably in a blender.
There are number of types of tablet presses or tableting 
machines, each varying in its productivity but similar in its 
basic operation. The operation is the compression of the tablet 
granulation within a steel die cavity by the pressure exerted 
by the movement of the two steel punches, a lower and upper 
punch.
Advantages of Wet Granulation19
1. The cohesiveness and compressibility of powders is 
improved due to the added binder that coats the individual 
powder particles causing them to adhere to each other so 
they can be formed into agglomerates called granules. By 
this method the properties of the formulation components 
are modified to overcome their tabletting deficiencies. 
During the compaction process, the granules are fractured 
exposing fresh powder surfaces, which also improve their 
compressibility. Lower pressures are therefore needed to 
compress the tablets resulting in improvements in tooling 
life and decreased machine wear. 
2. Drugs having a high dosage and poor flow and/or 
compressibility must be granulated by the wet method to 
obtain suitable flow and cohesion for compression. In this 
case, the proportion of the binder required to impart 
adequate compressibility and flow is much less than that 
of the dry binder needed to produce a tablet by direct 
compression.
3. Good distribution and uniform content for soluble, low-
dosage drugs and color additives are obtained if these are 
dissolved in the binder solution. This represents a distinct 
advantage over direct compression where the content 
uniformity of drugs and uniform color dispersion can be a 
problem.
4. A wide variety of powders can be processed together in a 
single batch and in so doing, their individual physical 
characteristics are altered to facilitate tabletting.
5. Bulky and dusty powders can be handled without 
producing a great deal of dust and airborne contamination.
Fluid-Bed Granulation9
The fluid-bed granulation method is an extension of 
wet granulation method, as it incorporates many of its 
concepts. In this method, particles of an inert material or the 
active drug are suspended in a vertical column with a rising 
air stream; while the particles are suspended, the common 
granulating materials in solution are sprayed into the column. 
There is a gradual particle buildup under a controlled set of 
conditions resulting in a tablet granulation that is ready for 
compression after the addition of the lubricant. The main 
benefit of this system is the rapid granulation and drying of a 
batch in a single piece of equipment. 
The rate of addition of the binder, temperature in the 
bed of particles, temperature of the air, volume and moisture 
of the air all play an important role in the quality and 
performance of the final product.
Dry Granulation
When tablet ingredients are sensitive to moisture or 
unable to withstand elevated temperatures during drying and 
when the tablet ingredients have sufficient inherent binding or 
cohesive properties slugging may be used to form granules. 
This method is referred as dry granulation, pre compression 
or double compression. Steps involved are weighing, mixing, 
slugging, dry screening, lubrication and compression.
The active ingredients, diluents (if required) and part 
of lubricants are blended. One of the constituents must have 
cohesive property. The powdered material is then “slugged” 
or compressed into large flat tablets or pellets of about 1 inch 
diameter. The slugs are then comminuted through desirable 
mesh screen either by hand or for larger quantities by mills. 
The lubricants remaining is added to the granulation and 
blended gently and the material is compressed into tablets.
Direct Compression
Direct compression consists of compressing tablets 
directly from powdered material without modifying the 
physical nature of the material itself. It involves only two 
operations, in sequence, powder mixing and tableting. The 
advantage of this is reduced cost production. The vehicles or 
carriers used must have good flow and compressible 
characteristics. Tablet excipients having the desired 
characteristics include:
Fillers – Spry dried lactose, microcrystalline cellulose, 
dicalcium phosphate, micro crystals of alpha monohydrate 
lactose.
Disintegrating agent – direct compression starch, 
sodium carboxy methyl starch, cross linked carboxy methyl 
cellulose fibres, cross linked polyvinyl pyrrolidone.
Lubricants – magnesim stearate, talc. 
Glidants – fumed silicon dioxide.
Typical unit operations involved in Wet 
granulation, Dry granulation and Direct compression11
Table 1
Wet 
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ion
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nts to 
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A Systemic and Modern Approach to Tablet Product 
Design
Tablet product design requires two major activities. 
First, formulation activities begin by identifying the 
excipients most suited for a prototype formulation of the drug. 
Second, the levels of those excipients in the prototype 
formula must be optimally selected to satisfy all 
process/product quality constraints13.
Factors Affecting the Type of Excipients Used in a 
Tablet Formulation
The type of excipients used may vary depending on a 
number of preformulation, medical, marketing, economic and 
process/product quality factors as discussed in the following 
sections. Here we mainly focus on the process/product 
quality.
Typical tests preformed on tablets are as follows:
 Weight variation
 Hardness 
 Friability
 Disintegration time
 Dissolution
 Water content
 Potency
 Content uniformity
Product quality is most often addressed at the tablet 
development stage. However, it is also important to monitor 
the processing quality of a formulation during development. 
They are:-
a. To optimize the process as well as the product.
b. To establish in-process quality control tests for routine 
production
It is more difficult to quantify the processing quality of a 
formulation than it is to measure the product quality. Some 
measurements that could be preformed on the process 
include:-
 Ejection force
 Capping
 Sticking
 Take-off force
 Flow of lubricated mixture
 Press speed (maximum)
 Frequency of weight control adjustments
 Sensitivity of formula to different presses
 Tooling wear
 Effect of consolidation load (Batch size)
 Hopper angle for acceptable flow
 Hopper orifice diameter for acceptable flow
 Compressional forces
 Environmental conditions (temperature, humidity and 
dust)
Each of the above processing parameters can become a 
source of trouble in scale-up (or) routine production. By 
monitoring these parameters in development, it may be 
possible to adjust the formula (or) process early enough to 
alleviate the source of trouble. The expected production 
output (number of tablets) per unit time will determine what 
speed tablet press will be required for a particular tablet 
product. If the anticipated unit output for a tablet product is 
expected to be large, a high-speed press will be required.
Attempts should be made in formulation development 
to design a tablet formula that will perform well on a high-
speed press. A formula to run on a high-speed press should 
have excellent flow to maintain uniform die fill during 
compressing. It should have good bonding characteristics so 
that it can compress with a minimal dwell time.
Compressed Tablets by Wet Granulation
Compressed tablets are defined as solid-unit dosage 
forms made by compaction of a formulation containing the 
drug and certain fillers (or) excipients selected to aid in the 
processing and properties of the drug product.
Formulation of Tablets and Factors to be Considered
The size and to some extent, the shape of the tablet are 
determined by the active ingredients. Drugs having very small 
doses in the microgram require the addition of fillers also 
called excipients to be added to produce a mass (or) volume 
of material that can be made into tablets of a size that is 
convenient for patients.
As the dose increases, so does the size of the tablet. 
Drugs with a dose of 100 to 200mg may require tablet 
weights of 150 to 300mg and round die diameters of 1/4 to 
7/16 inches. The diameter depends on the density and 
compressibility of the powders used. As the dose of the active 
ingredient increases, the amount of the excipients and the size 
of the tablet may vary considerably depending on 
requirements of each to produce an acceptable tablet. While 
the diameter of the tablet may in some cases be fixed, the 
thickness is variable thus allowing the formulator 
considerable latitude and flexibility in adjusting formulations.
As the dose, and therefore the size of the tablet 
increases, the formulator uses his expertise and knowledge of 
excipients to keep the size of the tablet as small as possible 
without sacrificing its necessary attributes.
Formulation of a tablet then requires the following 
considerations:
1. Size of the dose (or) quantity of active ingredients 
2. Stability of active ingredients.
3. Solubility of active ingredients.
4. Density of active ingredients.
5. Compressibility of active ingredients.
6. Selection of excipients.
7. Method of granulation (preparation for compression)
8. Character of granulation
9. Tablet press, type, size, capacity.
10. Environmental conditions (ambient (or) humidity 
control)
11. Stability of final product.
12. Bioavailability of the active drug content of the tablet.
The selection of excipients is critical in the formulation 
of tablets. Once the formulator has become familiar with the 
physical and chemical properties of the drug, the process of 
selecting excipients is begun. The stability of the drug should 
be determined with each proposed excipients. This can be 
accomplished as follows:
In the laboratory, prepare an intimate mixture of the 
drug with an excess of each individual excipients and hold at 
60˚C for 72 hrs in a glass container. At the end of this period 
analyze for the drug using a stability-indicating assay.
Tabletting Properties
Granules Size and Shape14
The size of the granule is known to affect the average 
tablet weight, tablet weight variation and disintegration time.
The size can be determined by using13
1. Optical micrometer
2. Sieving
3. Sedimentation
4. Particle volume measurement
5. Coulter counter
Surface Area
The determination of surface area of finely divided 
drug powders may be of value to drugs that have only limited 
water solubility. The two most common methods for 
determination of surface area of solid particles are:
a) Gas adsorption method (e.g. Quantasorb)
b) Air permeability technique (e.g. Fisher subsieve sizer)
Density
Granule density may influence compressibility, tablet 
porosity dissolution and other properties. The granule density 
is measured by pycnometer. The intrusion fluid used may be 
benzene (or) mercury.
Types of Densities
There are three types of densities:
1. True density: True density of the material itself exclusive 
of the voids and intra-particle pores larger than molecular 
(or) atomic dimensions in the crystal lattices.
2. Granule density: Granular density may be determined by 
the displacement of mercury which does not penetrate at 
ordinary pressure into pores smaller than about 10µm (or) 
by using pycnometer.
3. Bulk density: Bulk density is determined from the bulk 
volume and the weight. 
The bulk density of a powder is always less than the 
true density of its component particles, because the powder 
contains interparticle pores (or) voids
Bulk density α True density
Bulk density = K true density
K = Bulk density
True density
= packaging fraction (or) fractional solids. Content bulk 
density increases when particle size is more and if the particle 
size is less bulk density decreases.
Strength and Friability
A granule is an aggregation of compound particles i.e. 
held together by bonds of finite strength. The strength of a 
wet granule is mainly due to the surface tension of liquid and 
capillary forces. To determine granule strength two distinct 
types of measurements are made.
They are:
1. Compression strength
2. Friability measurement
Flow Properties
The flow properties of a material result from many 
forces. There are many types of forces that can act between 
particles.
1. Frictional force
2. Surface tension force
3. Cohesive (or) Vanderwaal force
4. Mechanical force
5. Electrostatic force
The tests to determine flow rate are of two types. They 
include direct methods and indirect methods.
Direct methods include hopper flow method and 
recording flow meter method.
Indirect methods include determination of angle of 
repose, measurement of bulk density and compressibility 
index, Carr’s index, Hausner’s ratio and angle of repose, 
shear cell determinations and critical orifice diameter 
determination.
Compressibility Index
This is an indirect method of measuring powder flow 
from bulk densities and was developed by “Carr”
Carr’s Index
It is given by the equation
Carr ' s index   Tapped density − Poured density
Tapped density
X 100
Carr’s index is related to flowability and is shown in 
the above information on compressibility index.
A similar index has been defined by Hausner.
Hausner ' s ratio = Tapped density
Poured density
Hausner’s ratio
< 1.25 – Good flow   =  20% Carr
>1.25 – Poor flow     =  33% Carr
1.25 > Hausner’s ratio < 1.5 Added glidant normally 
improves flow.
Angle of Repose
A static heap of powder, when only gravity acts upon it 
will tend to form a conical mount. If the horizontal surface 
radius is R and the height of the heap is H.
Then θ = tan-1 (H/R) where θ = angle of repose in 
degrees
Table 2
Angle of repose 
(θ)
Type of flow
< 25 Excellent
25 – 30 Good
30 – 40 Passable
> 40 Very poor
Solubility
Solid drugs, which are administered into the body, 
must undergo dissolution prior to absorption. So the solubility 
of dosage form is essential for the formation of solution. As a 
rule of thumb the compounds with aqueous solubility of less 
than 1% w/v are considered to posses dissolution related 
absorption problems.
The solubility of every new drug must be determined 
as a function of pH over pH range 1- 8. If the intrinsic 
dissolution rate was greater than 1mg/cm2/min. the absorption 
was greater than 1mg/cm2/min. the absorption was 
unimpeded. Dissolution rates of less than 0.1mg/cm2/min. 
were likely to give dissolution rate limited absorption since 
dissolution rate and solubility are proportional under sink 
conditions.
Different Adjuvants used in Tablet Formulation
In addition to the active or therapeutic ingredient, 
tablets contain a number of inert materials called as additives 
or excipients. Excipients are specified according to the 
function they perform in the tablet. They are classified as 
follows
 Fillers (Diluents)
 Binders
 Disintegrants
 Glidants
 Lubricants
 Antiadherents
 Adsorbents
 Moistening agents
 Coloring agents
 Sweetening agents
 Flavoring agents
Although they were considered to be inert they 
themselves should not exert therapeutic (or) biological action, 
it is now recognized that they can potentially influence rate 
and (or) extent of absorption. E.g. Formation of poorly 
soluble, non-absorbable drug-excipient complexes between 
tetracyclines and dicalcium phosphate, amphetamine and 
sodium carboxy methyl cellulose and phenobarbitone and 
PEG4000
Diluents or Fillers10
These are the inert substances which will increase the 
bulk of tablet. Selecting the diluent is an important character 
while tableting. These agents may not be necessary if the dose 
of drug per tablet is high. Generally, a tablet should weigh 
atleast 50mg and therefore very low dose drugs will 
invariably require diluents to bring the overall tablet weight to 
atleast 50mg.
Diluents or fillers fall into two general categories:
1. Carbohydrate and modified carbohydrate excipients.
2. Inorganic materials
In wet granulation process, such carbohydrate 
substances as sugars, starches and cellulose may also function 
as binder. Whereas in direct compression systems, they serve 
as diluent carrier. The inorganic excipients, when used in 
either system, are not binders that are a cohesive agent, in 
directly compressible system. Hence they function more as a 
carrier.
Microcrystalline cellulose (MCC) (AVICEL) is most 
widely used as direct compression tablet filler. It has a 
function of disintegrant besides that of a dry binder and is 
compatible with most excipients and active ingredients.
Lactose is an inexpensive, soluble and easily 
granulatable diluent. Since it lacks flowability and 
compressibility in its common form, lactose in modified form 
can only be used in direct compression.
The other commonly used diluents are mannitol, 
kaolin, dry starch, calcium sulfate, dicalcium phosphate.
Binders or Adhesives12
Binders are solid materials used in the manufacture of 
solid dosage forms because of their adhesive and cohesive 
properties. Their role is to assist size enlargement by adding 
cohesiveness to powders, thereby providing granules and 
tablets with necessary bond strength. They improve the 
appearance, hardness and friability of preparations but are not 
intended to influence the dissolution or disintegration of 
active substances.
Binders are either starch, gelatin, sugars or polymeric 
substances. The latter fall into two classes
a. Natural polymers such as starches or gum including 
acacia, tragacanth, gelatin.
b. Synthetic polymers such as poly vinyl pyrrolidone, methyl 
and ethyl cellulose and hydroxy propyl cellulose.
The quantity of binder used has a considerable effect 
on the characteristic of the compressed tablets. The use of too 
much binder or too strong binder will make a hard tablet that 
will not disintegrate easily. Binders are used both as solution 
and in dry form, depending on other ingredients in the 
formulation and method of preparation. However 
pregelatinized starches available are intended to be added in 
dry form so that water alone can be used for granulating 
solution.
Hydrophilic binders show better dissolution profiles 
with poorly soluble drugs like phenacetin by imparting 
hydrophilic properties to the granule surface. Non-aqueous 
binders like ethyl cellulose retard drug dissolution.
The direct compression method for preparing tablets 
requires a material that is not only free flowing but also 
sufficiently cohesive to act as a binder. For this 
microcrystalline cellulose, amylase and polyvinyl pyrrolidone 
is used.
MCC is a non fibrous form of cellulose. It is water 
insoluble but has the ability to draw fluid into tablet by 
capillary action. It swells on contact and thus acts as 
disintegrating agents. The material flows well and has a 
degree of self lubricating qualities.
Starch paste is a common binder. Starch extracted from 
maize, potato, rice, wheat is widely used as tablet binder. It 
has a concentration between 5 and 25%. It produces relatively 
soft and friable granules and tablets disintegrate readily. High 
viscosity is its draw back. Pregelatinized starch can be used 
instead of starch paste.
Disintegrants15,19
Disintegrant is the term applied to various agents 
added to tablet granulation for the purpose of causing the 
compressed tablet to break apart (disintegrate) when placed in 
aqueous environment. Basically the disintegrant’s major 
function is to oppose the efficiency of tablet binder and the 
physical forces that act under compression to form tablet. The 
stronger the binder, the more effective must be the 
disintegrating agent in order for the tablet to release its 
medication. Ideally it should cause the tablet to disrupt, not 
only into the granules from which it was compressed, but also 
into the powder particle from which the granulation was 
prepared.
The ideal disintegrant has-
1. Poor solubility
2. Poor gel formation 
3. Good hydration capacity
4. Good molding and flow properties
5. No tendency to form complexes with the drugs
There are two methods used for incorporating disintegrating agents into the 
tablet.
1. External addition
2. Internal addition
In external addition method, the disintegrant is added 
to the sized granulation with mixing just prior to compression. 
In the internal addition method, the disintegrant is mixed with 
some other powders before wetting the powder mixture with 
granulating solution. Thus, the disintegrant is incorporated 
within the granule. When this method is used, part of the 
disintegrant can be added internally, and part externally. This 
provides immediate disruption of tablet into previously 
compressed granules while the disintegrating agent within the 
granules produces further erosion of the granules to the 
original powder particles. The two step method usually 
produces better and more complete disintegration than the 
usual method of adding the disintegrant to the granulation 
surface only. 
Disintegrants act by different mechanisms:-
 They enhance action of capillaries in producing a rapid 
uptake of aqueous fluids. eg. Starch, microcrystalline 
cellulose.
 Those that swell on contact with water. eg. Sodium starch 
glycolate, carboxy methyl cellulose.
 That release gas to disrupt the tablet structure. eg. Certain 
peroxides.
 That destroys the binder by enzymatic action. eg. Starch 
amylase
Disintegrants constitute a group of material that on 
contact with water swell, hydrate, and change in volume or 
form, to react chemically to produce a disruptive change in 
tablet. These groups include various forms of starch, 
cellulose, bentonite, algins, vegetable gums, clays, ion 
exchange resins and acid base combinations. Carboxy methyl 
cellulose, corn and potato starch are popular disintegrants. 
They have great affinity for water and swell when moistened, 
then facilitating, the rupture of tablet matrix. Starch usually 5-
15% is used.
A decrease in amount of disintegrant can significantly 
lower bioavailability. Adsorbing disintegrants like bentonite 
and veegum should be avoided with low dose drugs like 
digoxin, alkaloids and steroids since a large amount of dose is 
permanently adsorbed and only a fraction is available for 
absorption.
A group of materials known as super disintegrants 
have gained popularity. Croscarmelose, crospovidone and 
sodium starch glycolate represent examples of a cross linked 
cellulose, a cross linked polymer and cross linked starch 
respectively.
Sodium lauryl sulphate in combination with starch is 
an effective disintegrant. In some cases the effectiveness of 
surfactants in improving tablet disintegration is postulated as 
due to an increase in the rate of swelling.
The binder, tablet hardness, lubricants can also affect 
disintegration time.
Glidants7
Glidants improve the flow characteristics of the 
powder mixture. These materials are added in the dry state 
just prior to compression. They act by reducing the inter-
particulate friction and reduce the frictional forces between 
the granules and dies. Colloidal silicon dioxide is the most 
commonly used glidant and generally used in low 
concentration of 1% or less. Talc is also used and may serve 
the dual purpose of glidant/ lubricant.
It is important to optimize the order of addition and 
mixing process of these materials to maximize their effect and 
to make sure that their influence on lubricants is minimized.
Lubricants
They have a number of functions in tablet manufacture:-
 They prevent adhesion of the tablet material to the surface 
of the dies and punches
 Reduce interparticle friction
 Facilitate the ejection of tablets from the die cavity
 Improves the rate of flow of tablet granulation
Commonly used lubricants include talc, magnesium 
stearate, calcium stearate, stearic acid, hydrogenated 
vegetable oils. Most lubricants are used in concentration 
below 1% when used alone. Talc is used in concentration as 
high as 5%. Lubricants are mostly hydrophobic materials. 
Poor selection or excessive amounts can result in water 
proofing the tablets, resulting in poor tablet disintegration and 
/ or delayed dissolution of drug substance.
Antiadherents
These are useful in tablet formulation, which have a 
tendency to pick easily. Multivitamin products containing 
high vitamin E levels often display extensive picking which 
can be minimized through the use of colloidal silica such as 
syloid (0.1-0.5%)
Adsorbents
Adsorbents are substances included in a formulation 
that are capable of holding quantities of fluids in an 
apparently dry state. Oil soluble drugs fluid extractors (or) 
oils can be mixed with adsorbents and then granulated and 
compressed into tablet.
Coloring Agents
Color helps the manufacturer to control the product 
during its preparation, as well as serving as means of 
identification to the users. All colorants used in 
pharmaceuticals must be approved by FDA. Lake is the 
combination of a water soluble dye to a hydrous oxide of a 
heavy metal resulting in an insoluble form of the dye. The 
most common method of adding color to a tablet formulation 
is to dissolve the dye in the binding solution prior to the 
granulation process. Migration of colors may be reduced by 
drying the granules slowly at lower temperature and stirring 
the granules while it is drying.
Different colorants used are D and C Red 33, Iron 
oxide, red-caramel, Titanium oxide, Cochineal extract.
Moistening Agents
In wet granulation a moistening agent is required 
usually water. In cases where, water cannot be used because 
of hydrolysis, alcohol is often substituted. Other moistening 
agents are industrial methylated spirits, isopropyl alcohol, etc.
Sweetening Agents
In addition to the sweetness which may be afforded by 
the diluents of the chewable tablet. eg. Mannitol (or) lactose. 
Sweeteners other than sugar that have an advantage of 
reducing the bulk volume are cyclamates, saccharin, 
aspartame (Searle)
Surfactants
Molecules (or) ions that are adsorbed at interfaces are 
termed as surfactants. Depending on the number and nature of 
the polar and non-polar groups presented, the amphiphile may 
be predominantly hydrophilic suggesting that the molecules 
(or) ion have a certain affinity for both polar and non-polar 
solvents.
The hydrophilic portion of the surfactant is soluble in 
the polar solvent and the lipophilic portion is soluble in the 
non-polar solvent. The surfactant occupies the interface to 
decrease interfacial tension and thereby increases the 
solubility. Release of poorly soluble drugs from tablet and 
hard gelatin capsules may be increased by the inclusion of 
surfactants in the formulations.
The ability of surfactants to reduce the solid liquid 
interfacial tension will permit gastrointestinal fluids to wet 
more effectively and to come into more intimate contact with 
solid dosage forms. This wetting effect may thus aid the 
penetration of GI fluids into the mass of capsule contents 
which often remains when hard gelatin shell has dissolved 
and reduces the tendency of poorly soluble drug particles to 
aggregate in the GI fluids. In each case the resulting increase 
in total effective surface area of drug in contact with the GI 
fluids would tend to increase the dissolution and absorption 
rate of drugs.
Production of Tablets
Tablets are made by compressing the formulation 
containing a drug or drugs with excipients on stamping 
machines called presses. Tablet compression machine or 
tablet presses are designed with the following basic 
components.
1. Hoppers for holding and feeding granulation to be 
compressed
2. Dies that define the size and shape of the tablet.
3. Punches for compressing the granulation within the dies.
4. Camtracks for guiding the movement of the punches.
5. A feeding mechanism for moving granulation from the 
hopper into the dies.
Punches and Dies
They are usually fabricated from special steels, the 
working surface being accurately machined and highly 
polished to ensure proper mechanical operation and well 
finished tablets.
Punches and dies (toolings) must be stored, lightly 
oiled, in containers which prevent accidental contact. The 
ease of manufacture and the final appearance of the tablet 
depend on unblemished, highly polished working surfaces. 
Punch edges must be sharp and free from burrs.
Working
Once the machine has been assembled, trial tablets 
may be made with the press. The optimum tablet hardness 
depends on the material to be compacted and the ultimate use 
of the tablets.
As the head of the press rotate, the punches are guided 
up and down by fixed cam tracks, which control the sequence 
of filling, compression and ejection. The portions of the head 
that hold the upper and lower punches are called the upper 
and lower turrets respectively and the portion holding the dies 
is called the die table. At the start of a compression cycle, 
granulation stored in a hopper empties into the feed frame 
which has several interconnected compartments. These 
compartments spread the granulation over a wide area to 
provide time for the dies. The pull down cam guides the lower 
punches to the bottom of their vertical travel, allowing the 
dies to overfill. The punches then pass over a weight control 
cam which reduces the fill in the dies to the desired amount. 
A wipe off blade at the end of the feed frame removes the 
excess granules and directs it around the turret and back into 
the front of the feed frame. Next the lower punches travel 
over the lower compression roll, while simultaneously the 
upper punches ride beneath the upper compression roll. The 
upper punches enter a fixed distance into the dies, while the 
lower punches are raised to squeeze and compact the 
granulation within the dies. After the movement of 
compression, the upper punches are withdrawn. The lower 
punches ride up the cam which brings the tablets flush with or 
slightly above the surface of the dies. The tablet strike a 
sweep-off blade affixed to the front of the feed frame and 
slide down a chute into a receptacle. At the same time the 
lower punches reenter the pulldown cam and the cycle is 
repeated.
EVALUATION OF TABLETS
In the evaluation of tablets the physical, chemical and 
bioavailability properties of tablets should be evaluated. The 
following are the different properties, which are to be 
evaluated.
Official Tests
Weight Variation1,3,7: 
The weight variation test would be satisfactory method 
for determining drug content uniformity and drug distribution. 
In practice, this test is performed by taking 20 tablets from a 
batch. Then 20 tablet, are weighed and the average weight is 
taken. Then the tablet is weighed individually. The percentage 
deviation can be determined by using the following formula.
Deviation = Average weight −Individual weight
Average weight
X 100
The percentage deviation limit based on average 
weight is shown in the following table according to I.P, B.P 
and U.S.P. 
Table 3
Sl. No Average weight 
(I.P)
Average weight 
(B.P)
Average weight 
(U.S.P)
% 
Deviation 
allowed
1 80mg (or) less 80mg (or) less 130mg (or) less 10.0
2 80-250 mg 80-250mg 130-324mg 7.5
3 >250mg >250mg >324mg 5.0
Hardness Test
Tablets require a certain amount of strength, or 
hardness and resistance to friability, to withstand mechanical 
shocks of handling in manufacture; packaging and shipping. 
The relationship of hardness to tablet disintegration and 
perhaps more significantly, to the drug dissolution release 
rate, has become apparent. The hardness of tablets from each 
batch can be tested by using Monsanto hardness tester. The 
tester consists of a barrel containing a compressible spring 
held between two plungers. The lower plunger is placed in 
contact with the tablet, and a zero reading is taken. The upper 
plunger is then forced against a spring by turning a threaded 
bolt until the tablet fractures. As the spring is compressed, a 
pointer rides along a gauge in the barrel to indicate the force. 
The force of fracture is recorded, and the zero force reading is 
deducted from it. The other hardness testers available are 
Pfizer tester, Strong-Cobb tester, Erweka tester and the 
Schleuniger tester.
Friability
It is a measure of tablet strength. The friability is 
determined by using Roche friabilator. This device, subjects a 
number of tablets to the combined effects of abrasion and 
shock by utilizing a plastic chamber that revolves at 25rpm, 
dropping the tablets at a distance of six inches with each 
revolution. Normally a preweighed tablet sample is placed in 
the friabilator, which is then operated for 100 revolutions. The 
tablets were then dusted and reweighed. The percentage 
weight loss was calculated by using the following formula.
F=100 X 1−w /wο 
Where,  wo =  Weight of tablets before friability
  w   =  Weight of tablets after friability
Conventional compressed tablets that do not lose more 
than 0.5 to 1.0% of their weight are generally considered 
acceptable. When capping is observed on friability testing, the 
tablet should not be considered for commercial use.
Disintegration
For most tablets the first important step towards 
solution is break down of the tablet into smaller particles or 
granules, a process known as disintegration. The time that it 
takes to disintegrates is measured in a device described in the 
USP/NF.
The apparatus consists of 6 glass tubes that are open at 
the top and held against a 10 mesh screen at the bottom end of 
the basket rack assembly. One tablet is placed in each tube, 
and basket rack is positioned in a 1L beaker of water or 
simulated gastric fluid at 37ºC ± 2ºC. A standard motor driven 
device is used to move the basket assembly containing the 
tablets up and down through a distance of 5 to 6 cm at a 
frequency of 28 to 32 cycles/min. Perforated plastic disc may 
also be used in the test which are placed on top of the tablets 
and impart an abrasion action on the tablets. Uncoated USP 
tablets have disintegration time standards as low as 5 min, but 
majority of the tablets have a maximum disintegration time of 
30min whereas for other coated tablets, the disintegration 
time will vary accordingly. 
Dissolution
The breakdown of tablet into granules and formation of 
clear solution is dissolution. According to IP, BP and USP/NF 
the various apparatus like rotating basket, rotating paddle and 
reciprocating cylinder, etc. are used to determine 
dissolution.Common dissolution tolerance in the USP/NF is 
not less than 75% dissolved in 45 min.
The pharmacopoeial requirements for dissolution tests 
are shown in the following table.
Table 4
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Acceptance criteria
S
1
6 Each unit is not less than D-5%
S
2
6
Average of 12 units (S1 + S2 ) is 
equal to (or) greater than D, and 
no unit is less than D-15%
S
3
1
2
Average of 24 units (S1 + S2 + S3) 
is equal to (or) greater than D, 
not more than 2 units are less 
than D-25%
D = The amount of dissolved active ingredients specified in 
monograph expressed as a percentage of the state amount.
Appearance
The general appearance of a tablet, its visual identity 
and overall “elegance,” is essential for consumer acceptance. 
The control of the general appearance of a tablet involves the 
measurement of a number of attributes such as a tablet’s size, 
shape, color, presence or absence of an odor, taste, surface 
texture, physical flaws and consistency, and legibility of any 
identifying markings.
DISSOLUTION
“Dissolution25 is defined as the process by which solid 
substances enters in solvent to yield a solution. 
Fundamentally, it is controlled by the affinity between the 
solid substance and the solvent.” The physical characteristics 
of the dosage form, the wettability of the dosage unit, the 
penetration ability of the dissolution medium, the swelling 
process, the disintegration and the deaggregation of the 
dosage forms are few of the factors that influence the 
dissolution characteristic of drugs. 
Wagner proposed a scheme for the processes involved 
in the dissolution of solid dosage forms.
Carstensen proposed a scheme incorporating some other 
factors in the following sequence9:
1. Initial mechanical lag
2. Wetting of the dosage form
3. Penetration of the dissolution medium into the dosage 
form
4. Disintegration 
5. Deaggregation of the dosage form and dislodgement of 
the granules
6. Dissolution
7. Occlusion of some particles of the drug.
In order for a drug to be absorbed, first it must be 
dissolved in the fluid at the absorption site. For instance, a 
drug administered orally in tablet or capsule form cannot be 
absorbed until the drug particles are dissolved by the fluids at 
some point within the gastrointestinal tract.
For instance, when the solubility of a drug is dependent 
upon either an acidic or basic medium, the drug would be 
dissolved in the stomach or intestines respectively. The 
process by which a drug particle dissolves is termed as 
dissolution. i.e. dissolution is the process by which a solid of 
only fair solubility characteristics enters into solution.
The rate of dissolution of drug substance is determined 
by the rate at which solvent-solute forces of attraction 
overcome the cohesive forces present in the solid. This 
process is rate-limiting when the release of solute into 
solution is slow and the transport into the bulk solution is fast. 
In this case the dissolution is said to be interfacially 
controlled. Dissolution may also be diffusion controlled, 
where the solvent-solute interaction is fast compared to 
transport of solute into the bulk solution. In diffusion-
controlled process, a stationary diffusion layer of solute 
adjacent to the solid/liquid interface is postulated. The 
saturation concentration of solute develops at the interface 
and decreases with distance across the diffusion layer.
Apparatus
The breakdown of tablet into granules and formation of 
clear solution is dissolution. According to IP, BP and USP/NF 
the following apparatus are used to determine dissolution.
1) Apparatus I ( Rotating Basket )
2) Apparatus II (Rotating Paddle )
3) Apparatus III (Reciprocating Cylinder)
4) Apparatus IV ( Flow through cell )
5) Apparatus V (Paddle Over Disk)
6) Apparatus VI (Cylinder)
Apparatus I (Rotating Basket Apparatus)
The assembly consists of the following, a covered 
vessel made of glass or other inert transparent material, a 
motor, a metallic drive shaft and a cylindrical basket. The 
vessel is partially immersed in a suitable water bath of any 
convenient size that permits holding the temperature inside 
the vessel 37±0.2 ºC during the test and keeping the bath fluid 
in constant smooth motion.
Apparatus that permits observation of the specimen 
and stirring element during the test is preferable. The vessel is 
cylindrical, with a hemispherical bottom. It is 180mm to 
175mm high, its inside diameter is 98mm to 106mm and its 
nominal capacity is 1000ml. Its sides are flanged at the top. A 
fitted cover may be used to retard evaporation. The shaft is 
positioned so that its axis is not more than 2mm at any point 
from the vertical axis of the vessel and rotates smoothly and 
without significant wobble. A speed-regulating device is used 
that allows the shaft rotation speed to be selected and 
maintained at the rate specified in the individual monograph, 
within ±4%. Shaft and basket components of the stirring 
element are fabricated of stainless steel, type 316 or 
equivalent, to the specifications. Unless otherwise specified in 
the individual monograph, use 40-mesh cloth or a basket 
having gold coating 0.0001-inch (2.5mm) thickness may be 
used. The dosage unit is placed in a dry basket at the 
beginning of each test. The distance between the inside 
bottom of the vessel and the basket is maintained at 25±2mm 
during the test.
Theory of Dissolution
Diffusion Layer Model (Film Theory) 8,26
In 1897 Noyes & Whitney developed an equation 
based on Fick’s 2nd law to describe the dissolution 
phenomenon. 
dc
dt
=K C s −C t   (1)
Where    dcdt → dissolution rate of the drug
  K  → Proportionality constant
Cs → Saturation concentration (maximum 
stability)
Ct → Concentration at time t
Cs – Ct → Concentration gradient
The proportionality constant K is also known as 
dissolution constant and the equation has been shown to obey 
first order kinetics.
In their experiments Noyes and Whitney maintained a 
constant surface area. However, because such a condition is 
not always applicable, Brunner and Tolloczko modified 
equation (1) to incorporate the surface area, S, as a separate 
variable.
dc
dt
=K 1 S C s −C t           (2)
In order to explain the mechanism of dissolution, 
Nernst in 1940 proposed the film-model theory. Under the 
influence of no reactive or chemical force, a solid particle 
immersed in a liquid, undergoes two consecutive steps
1. The solution of the solid at the interface, forming a thin 
stagnant layer of film ‘h’ around the particle and
2. The diffusion from this layer at the boundary to the bulk 
of the fluid.
In the 1st step, solution formation is almost 
instantaneous; in the 2nd step diffusion is much slower and, 
therefore, is the rate-limiting step.
By using Fick’s first law of diffusion and Nernst’s 
newly proposed film theory, Brunner expanded equation (2) 
to include the diffusion co-efficient, D. the thickness of the 
stagnant diffusion layer, h, and the volume of the dissolution 
medium, “v” producing
dc
dt
=K 2
DS
vh
C s −C t         (3)
The proportionality constant K2 is known as the 
intrinsic dissolution rate constant and is characteristic of each 
chemical compound.
Sink Condition
The term sink condition originated from the fact that 
the drug concentration on both sides of the epithelial layer of 
the internal wall approaches equilibrium in a short time, and 
that the gastrointestinal tract acts as a natural sink. i.e. the 
drug is absorbed instantaneously the moment it dissolves. 
Therefore, under in vivo conditions, there is no concentration 
build up and hence the retarding effect of the concentration 
gradient on the dissolution rate, as predicted by equation (1), 
does not occur. In order to simulate the in vivo sink condition, 
in vitro dissolution testing usually is conducted using either a 
large volume of the dissolution medium or a mechanism by 
which the dissolution medium is replenished constantly with 
fresh solvent at a specified rate so that the concentration of 
the solute never reaches more than 10 to 15% of its maximum 
solubility. If such a parameter is maintained, the dissolution 
testing is said to be conducted under sink conditions. i.e. not 
under the influence of the concentration gradient. This can be 
seen from the following mathematical gradient.
Assuming that Cs >> Ct, equation (3) becomes
dc
dt
=K 2
DS
vh
C s (4)
Cs and D are constants for each specific chemical 
substance. Therefore, they could be incorporated in K2 and 
appear in equation (5) as K3 
dc
dt
=K 3
S
vh          (5)
If the volume of the dissolution medium and the 
surface area are kept constant during the duration of the 
dissolution test, then
dc
dt
=K    (6)
Equation (6) predicts a constant dissolution rate under 
sink condition and represents a zero order kinetic process; i.e. 
the concentration of the drug increases linearly with time. 
Equation (6) is also believed to be approximate the in vivo 
condition where the dissolution rate of sparingly soluble 
drugs plays a fundamental role in determining their 
bioavailability.
Hixson & Crowell Cubic Root Law for Dissolution 
In equation (2), the surface area was considered 
constant for the duration of the dissolution test. Although this 
could be achieved by using a nondisintegrating disk of the 
chemical substance, a technique usually employed for the 
determination of the intrinsic dissolution rate, the same could 
not be maintained in dissolving crystal or a regular solid 
dosage form where a complete disintegration is a priority. 
Therefore, in order to develop a dissolution equation that is 
based on a changing surface area, Hixson and Crowell 
modified equation (2) to represent the rate of appearance of 
the solute in the solution by multiplying each side of the 
equation by v (volume), letting K1v = K
dW
dt
=KS C s −C t     (7)
Where, W  =  Weight of the solute in solution
They also assumed that S =kw 2 /3 , where k is a 
constant containing the shape factor and the density of the 
particle, and w is the weight of the undissolved particles at 
time t.
dW
dt
=Kkw 2/3 C s −C t  (8)
Dissolution
Absorption
(In vivo)
Dissolution
After mathematical treatment involving the application 
of  Fick’s first law and integration under the condition that w 
is equal to wo, the initial weight of the particle at time zero, 
equation (9) results.
w
ο1/3
− w1 /3=K 1 t (9)
Equation (9) is called the Hixson and Crowell’s “Cubic 
root law” for dissolution.
Wagner’s schematic diagram illustrates the processes involved 
in the dissolution of solid dosage forms
Factors Affecting the Rate of Dissolution Relating 
to the Solid Dosage Form
Factors affecting the dissolution rate of drugs from a 
dosage form include the following9,18,25:
1. Factors related to the physicochemical properties of the 
drug
2. Factors related to drug product information
3. Effect of processing factors on the dissolution rate
4. Factors related to the dosage form
5. Factors related to dissolution test parameters
6. Miscellaneous factors
Factors Related to the Physicochemical Properties of 
the Drug
Effect of Solubility
The modified Noyes and Whitney equation shows that 
the aqueous solubility of the drug is the major factor that 
determines its dissolution rate. The drug solubility data should 
be taken into consideration in the formulation design.
Effect of Particle Size
According to Nernst-Brunner theory, the dissolution 
rate is directly proportional to the surface area of the drug 
exposed to the dissolution media.  In order therefore to 
increase the dissolution rate for a given amount of drug, the 
effective surface area has to be increased. This can be 
achieved easily by decreasing the particle size of the drug. 
But the particle size reduction of the hydrophobic drug may 
produce a smaller effective area and a reduction in dissolution 
rate. The mechanism by which the reduction in particle size 
improves dissolution is usually through the enhancement of 
the drug solubility.
Effect of Solid Phase Characteristics of the Drug
Amorphicity and crystallinity, the two important solid-
phase characteristics of drugs affect their dissolution profile. 
Numerous studies have demonstrated that the amorphous 
form of a drug usually exhibits greater solubility and higher 
dissolution rate as compared to that exhibited by the 
crystalline form. For example, novobiocin and the 
contradictory example is that of erythromycin esteolate.
Effect of Polymorphism
Polymorphism and the state of hydration, salvation and 
/or complexation markedly influence the dissolution 
characteristics of the drug. Examples are tolbutamide, 
chloramphenicol and others.
Factors Related to Drug Product Formulation
Effect of Binding Agents
Binding agents are incorporated into tablets during 
granulation in order to improve the flowability of the drug 
and to enhance compressibility. These agents coat the drug 
particles and therefore the rate of solution of the binder in 
water can determine the release rate from the tableted drug. 
Tablets containing soluble binders (hydrolysed gelatin and 
PVP) had rapid dissolution rates whereas slow and 
incomplete disintegration of tablets formulated with starch 
paste led to protracted release of drug.
Effect of Disintegrants
To enhance the disintegration of tablets and capsules, 
disintegrants are added. Disintegrants act by either bursting 
open the tablet and/or promoting the rapid ingress of water 
into the center of the tablet or capsule. In many cases 
capillarity and therefore the rate of water penetration 
predominates in causing disruption. Sodium starch glycollate 
possesses high swelling capacity and high hydration capacity 
and is superior in dissolution properties than microcrystalline 
cellulose and cross-linked polyvinyl pyrrolidone
Effect of Lubricants
Lubricants are added to dosage form to prevent it from 
sticking to the processing machinery. Magnesium stearate, a 
hydrophobic-lubricant tends to retard the dissolution rate of 
salicylic acid tablets, while a water soluble surface active 
lubricant, sodium lauryl sulphate enhanced the dissolution. 
The enhancing effect of Sodium lauryl sulphate , on the other 
hand, was suggested to be due, in part, to an increase in the 
microenvironment pH surrounding the sparingly soluble weak 
acid and to increase wetting and better solvent penetration 
into the tablets and granules as a result of lowering the 
interfacial tension between the solid surface and the solvent. 
The most effective lubricants are very hydrophobic and they 
must therefore be properly formulated to avoid reducing 
dissolution rate and bioavailability.
Effect of Diluents
Increasing the starch content (most commonly using 
diluent) from 5 to 20% resulted in the dissolution rate of 
salicylic acid tablets. This was attributed to better 
disintegration. Later, Finholt suggested that the hydrophobic 
drug crystals acquire a surface layer of fine starch particles 
that imparts a hydrophilic property to the granular 
formulation and thereby increase the effective surface area 
and hence the dissolution rate.
Effect of Granulating Agents
Wet granulation has been shown to improve 
dissolution rates of poorly soluble drugs by imparting 
hydrophilic properties to the surface of the granules.
Factors Related to Processing 
Many processing factors used in tablet manufacturing 
greatly influence the dissolution rates of the active 
ingredients. The method of granulation, the size, density, 
moisture content and age of the granules as well as the 
compression force used in the tableting process, all contribute 
to the dissolution rate characteristics of the final product.
Method of Granulation
Granulation process, in general, enhances the 
dissolution rate of poorly soluble drugs, The use of fillers and 
diluents, such as starch, spray-dried lactose and 
microcrystalline cellulose, tend to increase the hydrophilicity 
of the active ingredients and improve their dissolution 
characteristics. In this regard, the wet granulation procedure 
was considered as a superior method compared to the dry of 
double compression procedure. With the advent of newer 
tableting machines and materials, it became more evident that 
the careful formulation and proper mixing sequence and time 
of adding the several ingredients are the main criteria that 
affect the dissolution characteristics of the tablets and not the 
method of granulation process.
Effect of Compression Force
T. Higuchi (1953), pointed to the great influence of the 
compressional force employed in the tableting process on the 
apparent density, porosity, hardness, disintegration time, and 
average primary particle size of compressed tablets. There is 
always a competing relationship between the enhancing effect 
due to the increase in surface area through the crushing effect 
and the inhibiting effect due to the increase in particle 
bonding that causes an increase in density and hardness and, 
consequently, a decrease in solvent penetrability. The high 
compression also may inhibit the wettability of the tablet due 
to the formation of a firmer and more effective sealing layer 
by the lubricant under the high pressure and temperature that 
usually accompanies a strong compressive force.
Factors Related to the Dosage Form
Drug Excipient Interaction
These interactions can occur during any unit operation, 
such as mixing, blending, drying, and/or granulating, resulting 
in a change in dissolution pattern of the dosage form in 
question. The effect of magnesium stearate on the 
disintegration time of tablets containing either potato starch or 
sodium starch glycolate was found to depend on the swelling 
characteristics of the disintegrants. By minimizing, if not 
eliminating, these interactions, adverse effects on the 
performance of the final product can be avoided. The better 
process control is also possible with noninteracting drug-
excipient interactions.
Deaggregation
Deaggregation is often a prerequisite for dissolution. In 
such cases it can control dissolution
Factors Related to Dissolution Test Parameters9,24
Agitation
The relationship between intensity of agitation and the 
rate of dissolution varies considerably according to the types 
of agitation used, the degree of laminar and turbulent flow in 
the system, the shape and design of the stirrer and 
physicochemical properties of the solid.
When a stirring device is used, such as the basket, 
paddle, or rotating filler, the speed of agitation generates a 
flow that continuously changes the liquid-solid interface 
between the solvent and the drug in a way similar to the flow 
rate in the flow-through dissolution apparatus. In order to 
prevent turbulence and sustain a reproducing laminar flow, 
which is essential for obtaining reliable results, either the 
speed of agitation or the flow rate, depending on the type of 
apparatus employed, should be maintained at a relatively low 
level.
The empirical relationship between the rate of dissolution and 
the intensity of agitation is 
K = a (N)b
Where N is the speed of agitation, K is the dissolution rate 
and a & b are constants.
Other factors that affect the correlation between 
agitation and dissolution rate include the density of the solid 
phase, the size and characteristics of the solid, the stirrer, the 
dissolution vessel and the heat of solution of the solute.
Temperature
Generally a temperature of 37ºC is always maintained 
during the dissolution determinations. The effect of 
temperature variation of the dissolution medium depends 
mainly on the temperature/solubility curves of the drug and 
excipients in the formulation. For a dissolved molecules, the 
diffusion coefficient, D, depends on the temperature T 
according to the Stokes equation.
D = kT (6πηr)
Where K is the Boltzmann constant and 6πηr is the Stokes 
force for a spherical molecule (η is the viscosity in cgs or 
poise units, and r is the radius of the molecule)
Dissolution Medium9
The selection of the proper fluid for dissolution testing 
depends largely on the solubility of the drug, as well as mere 
economics and practical reasons.
pH of Dissolution Medium
Great emphasis and effort was first placed on 
simulating in vivo conditions, especially pH, surface tension, 
viscosity, and sink condition. Most of the early studies were 
conducted in 0.1NHCL or buffered solutions with a pH close 
to that of the gastric juice (pH – 1.2). The acidic solutions 
tend to increase the dissolution rate by increasing the effective 
surface area. Because of the corroding action of the acid 
fumes on the dissolution equipment, currently it is a general 
practice to use distilled water unless investigate studies show 
a specific need for the acidic solutions in order to generate 
meaningful dissolution data. Another approach for avoiding 
the deleterious effects of hydrochloric acid is to replace it 
with acidic buffers, such as sodium acid phosphate, to 
maintain the required low pH.
Surface Tension of the Dissolution Medium
Surfactants and wetting agents lower the contact angle 
and thereby improve the penetration process of the matrix by 
the dissolution medium. Measurable enhancement in the 
dissolution rate of salicylic acid from an inert matrix was 
reported by Singh and co-workers when the contact angle,θ , 
was lowered from 92º (water) to 32º (using 0.01% dioctyl 
sodium sulfosuccinate). The surface tension also was 
correspondingly lowered from 60 to 31 dynes/cm. The same 
findings were obtained in benzocaine studies when 
polysorbate 80 was used as the surface-active agent. Low 
levels of surfactants were recommended to be included in the 
dissolution medium as this seemed to give a better correlation 
between the in vitro data and in vivo condition.
Viscosity of the Medium
In the case of diffusion-controlled dissolution 
processes, it would be expected that the dissolution rate 
decrease with an increase in viscosity. In the case of 
interfacial-controlled dissolution processes, however, 
viscosity should have very little effect. The Stokes-Einstein 
equation describes the diffusion coefficient, D, as a function 
of viscosity. 
Miscellaneous Factors
Adsorption
The adsorbent has an influence on the dissolution rate 
of a slightly soluble solid. It was also reported that the 
adsorbent is capable of increasing the dissolution rate 
observed in water under conditions of a decreased 
concentration gradient applying Nernst-Brunner film theory. 
Sorption
It was found that water sorption from the atmosphere 
into the tablet containing microcrystalline cellulose is a very 
rapid first-order process, resulting in substantial changes in 
the physical properties. These changes are attributed to the 
breaking of the hydrogen bonds. The relative density of the 
tablets was found to decrease, resulting in increased 
disintegration time with increase in water sorption-rate 
constants. These changes were found to be irreversible.
Humidity
Moisture has shown to influence the dissolution rate of 
many drugs from solid dosage forms. Environmental 
conditions to which dosage forms are exposed, moisture in 
particular, should be rigorously assessed if reproducible and 
reliable dissolution data are to be obtained. Additionally, 
humidity during the manufacture of the dosage forms should 
be carefully controlled to reproduce the quality of the product 
from batch to batch.
Detection Errors
Two most common variables leading to interlaboratory 
disagreement are the failure to use standards during analysis, 
and external vibration. Extreme care must be exercised when 
laboratory methods are introduced into quality control to 
ensure that no part of the equipment interferes with sensitive 
determinations. Despite the fundamental relationship between 
bioavailability and dissolution rate, the present evidence 
suggests that no single dissolution-rate test can be applied to 
all drugs.
Compendial Methods
When selecting apparatus for dissolution testing, 
routine quality control, new drug development, or complying 
with regulatory requirements, the analyst must follow the 
latest issue of compendia, including revisions.
DRUG PROFILE
PARACETAMOL27,28,28,30
Category
Analgesic, Antipyretic
Structure
OH
NH – CO– CH
3
Synonyms
Acetaminophen, N-Acetyl-p-aminophenol
Chemical Name
4-L Hydroxy Acetanilide
Molecular Formula
C8H9NO2
Molecular Weight
151.16
Dose
500mg to 1gm every 4-6 hrs. upto 4gm daily in divided 
dose.
Description
White odorless crystals (or) crystalline powder, tastes 
bitter.
Therapeutic Concentration
Plasma concentration 10-20µg/ml
Solubility
Freely  soluble in ethanol (95%) and in acetone. 
Sparingly  soluble in water, Very slightly soluble in 
chloroform. Practically  insoluble in ether. Soluble in 
solutions  of alkali hydroxides.
Dissociation Constant
pKa 9.5 (24°)
Melting Point
168˚C to 172˚C
Storage
Store in air tight, light resistant containers.
Standards
Paracetamol contains not less than 99.0% and not more 
than 101.05% or C8H9NO2 calculated with reference to the 
dried substance.
Identification
The infra red spectrum is concordant with the reference 
spectrum of paracetamol or with the spectrum obtained from 
paracetamol.
Adverse Effects
Side effects of paracetamol are usually mild, although 
hematological reactions have been reported. Skin rashes and 
other allergic reactions occur occasionally. Symptoms of 
paracetamol over dosage in the first 24 hours are nausea, 
vomiting, anorexia and abdominal pain.
Allergy
Fixed drug eruption due to paracetamol is reported.
Precautions
Paracetamol should be given with care to patients with 
impaired kidney or liver functions. It should also be given 
with care to the patients taking other drugs that effect liver.
Interaction
Alcohol-paracetamol hepatotoxicity was enhanced by 
alcohol in patients.
Mechanism of Action
The recent research (2) has shown the presence of a 
new, previously known cyclooxygenase enzyme COX-3, 
found in the brain and spinal cord, which is selectively 
inhibited by paracetamol, and is distinct from the two already 
known cyclooxygenase enzymes COX-1 and COX-2. It is 
now believed that this selective inhibition of the enzyme 
COX-3 in the brain and spinal cord explains the effectiveness 
of paracetamol in relieving pain and reducing fever without 
having unwanted gastrointestinal side effects.
Half Life
Adults – 1.5-3 hrs
Clearance
Plasma clearance about 5ml/min/kg
Protein Binding
Above 60µg/ml
Absorption and Fate
Paracetamol is readily absorbed from the gastro 
intestinal tract with peak plasma concentrations occurring 
about 30 min to 2 hrs. after ingestion. It is metabolized in the 
liver and excreted in the urine mainly as the glucoronide and 
sulphate conjugates. Less than 5% is excreted as unchanged 
paracetamol.
Uses
Paracetamol has analgesic and antipyretic actions 
similar to those of aspirin, but it has no useful anti-
inflammatory properties. The adult dose is 0.5gm to 1gm 
every 4 hrs upto a maximum of 4gm daily.
EXCIPIENTS PROFILE
STARCH20
Non Proprietary Names
BP: Maize starch, Potato starch, Rice starch, Tapioca 
starch, Wheat starch
Synonyms
Amido, amidon, amilo, amylum, Aytex P, Cassava 
starch.
Chemical Name
Starch
Empirical Formula
 (C6H10O5)n
Where n = 300 – 1000
Functional Category
Glidant, tablet and capsule diluent, tablet and capsule 
disintegrant, tablet binder.
Application In Pharmaceutical Formulation (or) 
Technology
Starch is widely used as an excipient primarily in oral 
solid dosage formulation where it is utilized as a binder, 
diluent and disintegrant.
As a diluent, starch is used for the preparation of 
standardized triturates of colorants or potent drugs to facilitate 
subsequent mixing or blending processes in manufacturing 
operations for volume adjustment of the fill matrix.
In tablet formulation, freshly prepared starch paste is 
used in concentration of 5-25% w/w in tablet granules as a 
binder. Selection of the quantity required in a given system is 
determined by optimization studies, using parameters such as 
granule friability, tablet friability, hardness, disintegration rate 
and dissolution rate. Starch is one of the most commonly used 
tablet disintegrant at concentration of 3-5%w/w.
Description
Starch occurs as an odorless and tasteless, fine white-
colored powder comprising of very small spherical or ovoid 
granules whose size and shape are characteristic for each 
botanical variety.
Stability and Storage Conditions
Dry, unheated starch is stable if protected from high 
humidity. When used as a diluent or disintegrant in solid 
dosage forms, starch is considered to be inert under normal 
storage conditions. However, heated starch solutions or pastes 
are physically unstable and are readily attached by micro-
organisms to form a wide variety of starch derivatives and 
modified starches which have unique physical properties.
PAPAYA PULP POWDER21,22,23
Papaya
The papaya (Carica papaya) is a long bulbous fruit 
with a point at the broad end. This large fruit has a thin 
greenish skin, which encloses a yellowish orange to pinkish 
red colored flesh. The center of the fruit is hollow with nestle 
black rounded seeds.
General Description 
The papaya is a common tropical fruit in India, often 
grown in family gardens. The papaya tree is unusual in 
structure as it consists of a very narrow straight trunk with no 
bark. The product papaya pulp is extracted from full unripe 
papaya, after blanching peeling, removing seeds and passing 
through 0.7mm sieve maintaining the essential composition 
and quality characteristics of natural papaya.
Solubility
Papaya is incompletely soluble in water or glycerol and 
it is mostly insoluble in most of the organic solvents.
Enzymes Present
Papain and chymo papain are the main enzymes 
present in papaya.
Applications
The ripe papaya fruit is stomachic, digestive, 
carminative, galactagogue and diuretic. It is effective in 
dysentery and chronic diarrhea.
Raw papaya is a good source of pectin that is widely 
used in fruit industry for preparation of jams, jellies. It is also 
used in textiles, explosives, lacquers, pharmaceutical, etc.The 
unripe fruit is laxative, diuretic, posses abortifacient activity.
TALC 
Non Proprietary Name
Purified talc, talc
Synonyms
Magsil osmanthus, Magsil star, powdered talc.
Empirical Formula
It is purified hydrated, magnesium silicate. 
Approximate formula:  Mg6(Si2O5)4
It may contain small amounts of aluminum silicate and 
iron.
Functional Category
Glidant, tablet and capsule diluent, tablet and capsule 
lubricant
Applications in Pharmaceutical Formulation (or) 
Technology
It is widely used in oral solid dosage formulations as a 
glidant and diluent. It is also used in topical preparations of 
dusting powder, although it should not be dust in surgical 
gloves. It is additionally used to clarify liquids and is also 
used only for its lubricant properties in cosmetics and food 
products.
Table.5
Description
It is a very fine white to grayish white colored, 
odorless, crystalline powder. It adheres readily to the skin, 
soft to touch and free from grit.
Stability and Storage Conditions
Talc is a stable material. Talc should be stored in a 
well-closed container in a cool, dry place.
Incompatibility
Incompatible with quaternary ammonium compounds.
Safety
Talc is mainly used in tablet and capsule formulations. 
Following oral ingestion talc is not absorbed systemically and 
may thus be regarded as an essentially nontoxic material. Talc 
is an irritant if inhaled and prolonged excessive exposure may 
cause pneumoconiosis. Eye protection, gloves and a respirator 
are recommended.
MAGNESIUM STEARATE
Non Proprietary Name
BP : Magnesium stearate
USPNF : Magnesium stearate
Synonyms
Magnesium octa decanoate, stearic acid magnesium 
salt.
Chemical Name
Octadecanoic acid magnesium salt.
Empirical Formula and Molecular Weight
C36H70MgO4
591.27
Functional Category
Tablet and capsule lubricant.
Applications in Pharmaceutical Formulation (or) 
Technology
Magnesium stearate is widely used in cosmetics, foods 
and pharmaceutical formulations. It is primarily used as a 
lubricant in capsule and tablet manufacture of concentrations 
between 0.25 to 5.0%
Description
Magnesium stearate is a fine white precipitate or 
milled powder of low density, having faint, characteristic 
odor and taste. The powder is greasy to touch and readily 
adheres to skin.
Stability and Storage Conditions
Magnesium stearate is stable and should be stored in a 
well-closed container in a cool dry place.
Incompatibility
Incompatible with strong acids, alkali and iron salts. 
Avoid mixing with strong oxidizing materials.
Safety
Magnesium stearate is widely used as a pharmaceutical 
excipient and is generally regarded as being non toxic 
following oral administration. However, oral consumption of 
large quantities may result in some laxative effect or mucosal 
irritation. Inhalation of magnesium stearate powder is harmful 
and has resulted in fatalities.
LACTOSE
Nonproprietary Names
BP: Lactose
Synonyms
Lactochem, lactohale, lactopress, microfine, microtose, 
milk sugar, pharmatose, respitose, tablettose, wyndale.
Chemical Name
O-β-D-Galactopyranosyl-(1→4)-α-D-glucopyranose 
anhydrous.
O-β-D-Galactopyranosyl-(1→4)-α-D-glucopyranose 
monohydrate.
Empirical Formula and Molecular Weight
C12H22O11                & 342.30 (anhydrous)
C12H22O11 .H2O    & 360.31 (monohydrate)
Functional Category
Diluent for dry-powder inhalers, tablets and capsules.
Applications in Pharmaceutical Formulation or Technology
Lactose is widely used as a filler or diluent in tablets, 
capsules and dry-powder inhalations and to a more limited 
extent in lyophilized products and infant feed formulas. 
Various lactose grades commercially available are 
selected on the basis of dosage form being developed. Lactose 
is used in combination with sucrose (approximately 1:3) to 
prepare sugar-coating solutions. 
Description
Lactose occurs as white or off-white crystalline 
particles or powder. Lactose is odorless and slightly sweet 
tasting; α-lactose is approximately 15% as sweet as sucrose, 
while β-lactose is sweeter than the α-form. Several different 
forms of lactose are commercially available: anhydrous α-
lactose, α-lactose monohydrate and to a lesser extent, 
anhydrous β-lactose. 
Stability and Storage Conditions
Lactose may develop a brown coloration on storage, 
the reaction being accelerated by warm, damp conditions. The 
color stabilities of various lactoses also differ.  Saturated 
solutions of β-lactose may precipitate crystals of α-lactose on 
standing. Solutions also show mutarotation. Lactose should be 
stored in a well-closed container in a cool, dry place.
Incompatibilities
Incompatible with amino acids, aminophylline, 
amphetamines and lisinopril.
Safety
Adverse reactions like abdominal cramps, diarrhea, 
distension and flatulence to lactose are largely attributed to 
lactose intolerance, which in persons with a deficiency of the 
intestinal enzyme lactase. Lower doses of lactose produce 
fewer adverse effects, and lactose is better tolerated if taken 
with other foods.
Handling Precautions
Normal precautions appropriate to the circumstances 
and quantity of material handled should be observed. 
Excessive generation of dust, or dust inhalation, should be 
avoided.
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OBJECTIVE OF THE WORK
The objective of the present work is:
 To  study  the  effect  of  disintegrating  and  binding  agents  on  the 
dissolution of formulation containing paracetamol
 To establish the use of a natural binding and disintegrating agent papaya 
pulp powder in formulating oral dosage form. i.e. tablets.
 To find out the suitable method of incorporation of papaya pulp powder 
as disintegrant
 To  find  out  a  suitable  concentration  of  papaya  pulp  powder  as 
disintegrant in the best method of addition of disintegrant.
 To evaluate the formulated tablets.
The present work was carried out in the following lines
 Preformulation studies were carried out on the purity of the drug and its 
compatibility between the additives used by the IR spectral analysis.
 Formulation  of  tablets  containing  paracetamol  using  papaya  pulp 
powder as disintegrant, lactose as diluent, starch as binder, magnesium 
stearate as glidant and talc as lubricant.
  Papaya pulp powder is added in three methods to the drug 
a. Internal method (prior to granulation) 
b. External method (prior to compression)
c. Internal and external method (half portion prior to granulation and 
half portion prior to compression)
 In vitro evaluation of the formulated tablets.
MATERIALS AND EQUIPMENTS
MATERIALS USED
Table 6
Materials Grade Source
Paracetamol IP Vega pharmaceuticals
Papaya pulp powder IP Natural source
Lactose IP S.D.fine chem Limited
Maize starch IP Loba chemi Pvt. Limited
Magnesium stearate IP Loba chemi Pvt. Limited
Talc IP
Himedia laboratories 
Pvt.Limited
EQUIPMENTS USED
Table 7
Equipment Model / Company
UV-visible spectrophotometer Jasco V-530
FT-IR spectrophotometer Jasco 410
Digital balance Denver Instruments XP-300
Balance Dhona 200-D
Hot air oven Inlab Equipments (Madras) Pvt.Ltd
Disintegration apparatus Remi Equipments
Dissolution test apparatus Electrolab
Friabilator Excel Enterprises, Kolkata
Tablet punching machine Rimex Mini Press
Sieves Tayant Scientific Industries, Mumbai
Hardness tester Pfizer
Tray drier Cadmach-Bom
PREFORMULATION STUDIES
Before formulation of drug substances into a dosage 
form, it is essential that it should be chemically and physically 
characterized. Preformulation studies give the information 
needed to define the nature of the drug substance and provide 
a framework for the drug combination with pharmaceutical 
excipients in the fabrication of a dosage form.
In the present work, preformulation studies on the 
purity, development of calibration curve of the drug candidate 
and the compatibility between drug and excipients were 
carried out.
Development of Calibration Curve for Paracetamol
Spectral Measurement
The standard solution of Paracetamol was scanned at 
249nm using UV-visible spectrophotometer. 
Standard Graph of Paracetamol 
A spectrophotometric method based on the 
measurement of absorbance at 249nm in phosphate buffer of 
pH 7.8 was used in the present study for the estimation of 
Paracetamol 
An accurately weighed 10mg of Paracetamol was 
dissolved in phosphate buffer of pH 7.8 in a 100ml volumetric 
flask and the solution was made upto the volume with 
phosphate buffer of pH 7.8 to give 100μg/ml solution. A little 
quantity of methanol was used to dissolve paracetamol. From 
the above solution 1, 2, 3, 4 and 5ml was diluted to 10ml 
using phosphate buffer  pH 7.8 to obtain a series of dilutions 
containing 10, 20, 30, 40 and 50 µg/ml of solution. These 
solutions were scanned at 249nm using a Shimadzu 1400 
double beam UV-Visible spectrophotometer At this 
wavelength, the absorbances of all the other solutions are 
measured using the phosphate buffer of pH 7.8 as blank. The 
concentration of paracetamol and the corresponding 
absorbance values are given in Table.8. The absorbance 
values were plotted against concentrations of paracetamol.The 
method obeyed Beer-lambert’s law in the concentration range 
of 10-50 µg/ml. 
Compatibility Studies
One of the requirements for the selection of suitable 
excipients or carrier for pharmaceutical formulation is its 
compatibility. Therefore in the present work, a study was 
carried out by using infrared spectrophotometer to find out if 
there is any possible interaction between paracetamol and its 
excipients.
Weighed amount of drug (3mg) was mixed with 
100mg of potassium bromide (dried at 40-50ºC). The mixture 
was taken and compressed under 10-ton pressure in a 
hydraulic press to form a transparent pellet. The pellet was 
scanned from 4000-400cm-1 in IR spectrophotometer.
IR Spectral Analysis
Using FTIR 410 PC spectrometer the compatibility 
studies between drug and the carrier was carried out.
There was no appearance or disappearance of any 
characteristic peak, which confirms the absence of chemical 
interaction between drug and carrier.
CALIBRATION CURVE OF PARACETAMOL
Table 8
S. No Concentration (mcg/ml) Absorbance at  290nm
1 0 0.0000
2 10 0.1986
3 20 0.3988
4 30 0.6014
5 40 0.7958
6 50 0.9043
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FORMULATION OF PARACETAMOL TABLETS
Manufacturing of Paracetamol Tablets
The characteristics of a tablet that makes it a popular 
oral dosage form, e.g. compactness, physical stability, rapid 
production capability, chemical stability and efficacy are 
dictated primarily by the qualities of the granules from which 
it is made. The ideal physical form for compaction into a 
tablet is a sphere. Therefore granulation is done to convert 
powdered materials into regularly shaped aggregates called 
granules.
Preparation of tablet involved the following steps:
a. Mixing
b. Granulation
c. Compression
Preparation of Granules by Wet Granulation Method
The first step i.e. mixing was done by geometric 
dilution method. Before mixing, all the powders were passed 
through a sieve. In the method of internal addition of 
disintegrant, required amount of drug (Paracetamol) lactose, 
papaya pulp powder as disintegrant, each in the concentration 
of 2%, 4%, 6%, 8% and 10% were added individually and 
triturated for 20 minutes in a mixer.
The binding solution which was prepared by dispersing 
starch in hot demineralized water was then added to the above 
sieved and mixed mixtures slowly with constant stirring until 
a coherent mass was obtained. The above wet granules were 
subjected to semi drying for 15 minutes at 45-50˚C. Then 
immediately the wet mass sieved to prepare wet granules 
through sieve no 12. Dried the granules at 45-50˚C till the 
loss on drying is 3-3.5%. The dried granules were passed 
through the sieve no.14. The above mixture was lubricated 
with talc and magnesium for 30 minutes. 
Method
Fifteen formulations (F1 – F15) were formulated using 
natural disintegrant Papaya pulp powder in various 
concentrations of 2%, 4%, 6%, 8% and 10%
In formulations (F1 – F5) papaya pulp powder was 
added as internal disintegrant. In those formulations the 
disintegrant was mixed in different concentrations 2%, 4%, 
6%, 8% and 10% respectively with the required amount of 
drug and the diluent lactose prior to granulation.  To the 
prepared granules, magnesium stearate and talc were added as 
glidant and lubricant respectively. All these were mixed 
uniformly.
In formulations (F6 – F10) papaya pulp powder was 
added both as internal and external disintegrant. In those 
formulations the disintegrant was mixed in different 
concentrations 2%, 4%, 6%, 8% and 10% respectively half 
prior to granulation of the drug and lactose, and half prior to 
compression of the granules. To the prepared granules, 
magnesium stearate and talc are added as glidant and 
lubricant respectively. All these were mixed uniformly.
In formulations (F11 – F15) papaya pulp powder was 
added as external disintegrant. In those formulations the 
disintegrant was mixed in different concentrations 2%, 4%, 
6%, 8% and 10% respectively to the granules prior to 
compression. To the prepared granules, magnesium stearate 
and talc were added as glidant and lubricant respectively. All 
these were mixed uniformly.
The practical weight loss of the tablets was calculated 
and the tablets were punched keeping the hardness of the 
tablets between 3-5 kg/sq.cm. The tablets were then 
evaluated.
Tablet formulations containing paracetamol with papaya pulp powder 
as internal disintegrant in different concentrations
Table 9
Sl.No Ingredients Product codeF1(mg) F2(mg) F3(mg) F4(mg) F5(mg)
1 Paracetamol 250 250 250 250 250
2 Lactose 190 180 170 160 150
3 Papaya pulp powder 2% 4% 6% 8% 10%
4 Starch q.s q.s q.s q.s q.s
5 Magnesium stearate 25 25 25 25 25
6 Talc 25 25 25 25 25
Average weight of 
tablet
500 500 500 500 500
Tablet formulations containing paracetamol with papaya pulp powder 
as both internal and external disintegrant in different concentrations
Table 10
Sl.No Ingredients Product codeF6(mg) F7(mg) F8(mg) F9(mg) F10(mg)
1 Paracetamol 250 250 250 250 250
2 Lactose 190 180 170 160 150
3 Papaya pulp powder 2% 4% 6% 8% 10%
4 Starch q.s q.s q.s q.s q.s
5 Magnesium stearate 25 25 25 25 25
6 Talc 25 25 25 25 25
Average weight of 
tablet
500 500 500 500 500
Tablet formulations containing paracetamol with papaya pulp powder 
as external disintegrant in different concentrations
Table 11
Sl.No Ingredients Product codeF11(mg) F12(mg) F13(mg) F14(mg) F15(mg)
1 Paracetamol 250 250 250 250 250
2 Lactose 190 180 170 160 150
3 Papaya pulp powder 2% 4% 6% 8% 10%
4 Starch q.s q.s q.s q.s q.s
5 Magnesium stearate 25 25 25 25 25
6 Talc 25 25 25 25 25
Average weight of 
tablet
500 500 500 500 500
EVALUATION OF TABLETS
All the formulated dosage forms of paracetamol tablets 
have been subjected to the following quality control tests7, 3:
1. Weight Variation
2. Hardness
3. Friability
4. Uniformity of Dispersion
5. Disintegration
6. Dissolution
Weight Variation: 
The USP weight variation test is performed by taking 
20 tablets from a batch. Then 20 tablet, are weighed and the 
average weight is taken. Then each tablet is weighed 
individually. The percentage deviation can be determined by 
using the following formula.
Deviation = Average weight −Individual weight
Average weight
X 100
All the batches of the formulated tablets passed the 
weight variation test according to IP, BP and USP.
Hardness Test
Pfizer hardness tester was used for measuring the 
hardness of the formulated paracetamol tablets. From each 
batch five tablets were taken at random and subjected to test. 
The mean of these five tablets are given in the table.12
Friability
It is a measure of tablet strength. The friability is 
determined by using Roche Friabilator. 10 tablets were taken 
and their weight determined. Then they were placed in the 
friabilator and allowed to make 100 revolutions at 25rpm. The 
tablets were then dusted and reweighed. The percentage 
weight loss was calculated by using the following formula.
F=100 X 1−w /wο 
Where,    wo  =  Weight of tablets before friability
    w   =  Weight of tablets after friability
All the batches of the formulated paracetamol tablets 
were found to be within the official specified limits.
Uniformity of Dispersion
Place two tablets in 100ml water. Stir gently until 
completely dispersed. A smooth dispersion is obtained which 
passes through sieve screen 710µm (sieve no 22).
Disintegration
The USP apparatus to test disintegration consists of 6 
glass tubes that are open at the top and held against a 10 mesh 
screen at the bottom end of the basket rack assembly. One 
tablet is placed in each tube, and basket rack is positioned in a 
1L beaker of water or simulated gastric fluid at 37ºC ± 2ºC. A 
standard motor driven device is used to move the basket 
assembly containing the tablets up and down through a 
distance of 5 to 6 cm at a frequency of 28 to 32 cycles/min. 
Perforated plastic disc may also be used in the test. The 
results were given in the table.12.
Dissolution
The breakdown of tablet into granules and formation of 
clear solution is dissolution. 
Apparatus II
Dissolution was carried out using USP dissolution 
apparatus 2 (Rotating paddle apparatus). Dissolution of 
tablets was carried out in 900ml-dissolution medium.The 
dissolution medium for paracetamol tablet was pH 7.8. The 
temperature of dissolution medium was maintained at 37ºC ± 
2ºC. The agitation intensity was 50rpm. The sampling time 
specified was modified instead of withdrawing a single 
sample at 5-min interval serial sampling was done at 0, 5, 10, 
15, 20, 25 and 30 min for uncoated tablets. Equal volume of 
fresh medium having same temperature was replaced at each 
time. The samples were suitably diluted and the amount of 
active ingredient was determined spectrophotometrically with 
respect to the reported methods.
Tolerances
Not less than 80% (Q) of the labeled amount of 
C8H9NO2 paracetamol is dissolved in 30 minutes.
RESULTS OF EVALUATION PARAMETERS
Table 12
Sl.No
Product 
code
Disintegration 
time (min)
Average 
weight 
(mg)
Uniformity 
weight (mg)
Hardness
(Kg/cm2)
Friability 
(%)
1 F1 8.00 498.5 498 to 500 4.9 0.95
2 F2 7.30 499.5 497 to 502 4.5 0.82
3 F3 7.15 500.0 498.5 to 502 4.5 0.84
4 F4 6.40 501.0 498 to 503.5 4.0 0.91
5 F5 6.00 500.5 499 to 502 4.7 0.86
6 F6 5.00 500.0 497.5 to 502 4.1 0.85
7 F7 4.40 501.5 498 to 501 3.9 0.84
8 F8 4.30 499.0 497 to 500 4.5 0.92
9 F9 4.30 500.0 497 to 502.5 3.7 0.90
10 F10 4.15 502.5 499.5 to 503.5 4.9 0.94
11 F11 3.00 498.5 497 to 501 4.0 0.82
12 F12 3.00 502.0 498 to 504 4.1 0.88
13 F13 3.00 501.0 497.5 to 502.5 3.5 0.92
14 F14 2.45 499.0 498 to 502 4.5 0.85
15 F15 2.10 500.0 498 to 502.5 3.9 0.90
DISSOLUTION RATE OF PARACETAMOL
Dissolution  rate  of  paracetamol  with  papaya  pulp  powder  in  2% 
concentration
Table 13
Sl.No Time (min)
Percentage released
F1 (internal)
F6(internal 
& external)
F11(external)
1 5 20.7 25.2 37.8
2 10 39.6 40.5 50.4
3 15 50.4 59.4 70.2
4 20 60.3 66.6 82.8
5 25 74.7 78.3 90.9
6 30 80.1 86.4 91.8
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Dissolution  rate  of  paracetamol  with  papaya  pulp  powder  in  4% 
concentration
Table 14
Sl.No Time (min)
Percentage released
F2 (internal)
F7(internal 
& external)
F12(external)
1 5 21.6 26.1 48.6
2 10 42.3 45 62.1
3 15 54.9 59.4 71.1
4 20 64.8 71.1 87.3
5 25 79.2 81 90.9
6 30 82.8 86.4 91.8
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Dissolution  rate  of  paracetamol  with  papaya  pulp  powder  in  6% 
concentration
Table 15
Sl.No Time (min)
Percentage released
F3 (internal)
F8(internal 
& external)
F13(external)
1 5 22.5 27.9 51.3
2 10 33.2 46.8 65.7
3 15 58.5 63 81
4 20 67.5 75.6 88.2
5 25 80.1 81.9 91.8
6 30 83.7 87.3 92.7
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Dissolution rate of paracetamol with papaya pulp powder in 8% 
concentration
Table 16
Sl.No Time (min)
Percentage released
F4 (internal)
F9(internal 
& external)
F14(external)
1 5 23.4 30.6 53.1
2 10 33.2 54 67.5
3 15 60.3 63 84.6
4 20 68.4 74.7 88.2
5 25 81 83.7 91.8
6 30 83.7 88.2 94.5
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Dissolution  rate  of  paracetamol  with  papaya  pulp  powder  in  10% 
concentration
Table 17
Sl.No Time (min)
Percentage released
F5 (internal)
F10(internal 
& external)
F15(external)
1 5 25.2 32.4 55.8
2 10 30.6 50.4 72.9
3 15 62.1 64.8 85.5
4 20 69.3 76.5 90.9
5 25 82.8 85.5 94.5
6 30 84.6 89.1 96.3
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RESULTS AND DISCUSSION
An attempt was made to identify the best method of 
addition of the natural disintegrating agent papaya pulp 
powder in the formulation of paracetamol tablets. To find the 
best method of addition, three methods of addition of 
disintegrating agents were used and fifteen formulations were 
prepared. All the formulations were subjected to in vitro 
evaluation and the results were compared.
Fifteen different formulations F1 to F15 were prepared 
using papaya pulp as internal, external and both as internal 
and external disintegrant each in the concentration of 2%, 4%, 
6%, 8% and 10%
Observing the evaluation results for disintegration it 
was found that F15 containing papaya pulp powder as the 
external disintegrant in the concentration of 10% disintegrated 
faster than the others. It was then followed by F14 and then F13
The results obtained for the other parameters like 
weight variation, hardness and friability were within the 
specific limit for tablet formulation. 
From the results obtained from dissolution studies it 
was seen that formulations (F14 and F15) containing papaya 
pulp powder as external disintegrant (concentration 8% and 
10%) exhibited better dissolution characteristics when 
compared to other formulations.
Out of the fifteen formulations F15 containing papaya 
pulp powder as the external disintegrant in the concentration 
10% was found to be the best formulation since it showed 
good dissolution and disintegration characteristics.
Nevertheless formulation F14 containing papaya pulp 
powder as external disintegrant showed good disintegration 
and dissolution characteristics which were found to be within 
the limits specified in the pharmacopoeia.
Formulations F11, F12, F13 and F14 containing papaya pulp 
powder as the external disintegrant also exhibited good 
disintegration and dissolution characteristics.
All the formulations were prepared by wet granulation 
method and all of them showed good flow properties and 
compression characteristics.
SUMMARY AND CONCLUSION
An attempt was made to study the use and the best 
method of incorporation of papaya pulp powder as a 
disintegrant in the formulation of paracetamol tablets. In order 
to find out the percentage and the best method of 
incorporation of the papaya pulp powder that could be used to 
formulate a product containing good disintegration and 
dissolution characteristics, different concentrations of the 
papaya pulp powder was used. Fifteen formulations were 
prepared with a natural disintegrant papaya pulp powder in 
the concentration of 2%, 4%, 6%, 8% and 10%. The papaya 
pulp powder is incorporated in the formulation by three 
methods. i.e. internal method, both internal and external 
method and external method. The tablets were evaluated and 
results were compared with each other. Among the 
formulated tablets it was found that F15 containing papaya 
pulp powder as external disintegrant showed good dissolution 
and disintegration characteristics.
Although the disintegration and dissolution 
characteristics of the formulation containing papaya pulp 
powder as internal disintegrant were lower than the other 
formulation, they were within the limits specified in the 
pharmacopoeia. The results indicated that external method of 
incorporation of papaya pulp powder results in faster 
dissolution than internal and external method of incorporation 
which is in turn superior to internal method of incorporation. 
Its characteristics can further be improved by varying the 
concentration of papaya pulp powder
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